NAFLD vs NASH: Is your patient at risk?
Nonalcoholic fatty liver disease (NAFLD) vs Nonalcoholic steatohepatitis (NASH)
PART 2 of two CME articles that look at liver transaminase levels, signs, symptoms, causes, diagnosis, and management. (eligible for CME credit. Read both and follow the link for the online FibonacciCME test)
Part I. Transaminitis Part II. Nonalcoholic Fatty Liver Disease
Continuing Medical Education
Eligible for CME Credit
FREE Online CME Test on FibonacciMD.app
Nonalcoholic steatohepatitis (NASH), a form of liver disease, is associated with obesity, high blood pressure, type-2 diabetes, high cholesterol and triglyceride levels, use of certain medications, and genetics. In addition, it commonly is seen among patients with metabolic syndrome and insulin resistance. NASH is most prevalent during middle age, but it has been seen in pediatric populations. Primary complications of the disease include ﬁbrosis, cirrhosis, and liver cancer.
Nonalcoholic fatty liver disease (NAFLD), a condition caused by fat accumulation in the liver, may progress to NASH, which includes further fat accumulation and progressive inﬂammation. Increased inﬂammation can lead to scarring of the liver and/or cirrhosis. Approximately 20% of people with NAFLD develop NASH, and some 12% of NASH patients develop cirrhosis.
Signs and symptoms associated with NAFLD include enlarged liver, obesity, elevated serum liver transaminase levels, and insulin resistance. Evidence of liver ﬁbrosis can be identiﬁed by utilizing the NASH Fibrosure blood test, magnetic resonance elastography or vibration-controlled transient elastography. Consider one of these assessments if the patient is at higher risk for developing steatohepatitis (e.g., those with poorly controlled diabetes).
Pathologic evaluation by biopsy is the most accurate way to truly distinguish NAFLD from NASH; however, the need for a biopsy should be decided by either a hepatologist or an experienced gastroenterologist. The primary physician should try to exclude other causes of elevated liver transaminases, such as alcohol consumption, viral hepatitis , autoimmune disease, or hemochromatosis.
The association between genetic variations and NAFLD and NASH is being widely studied. Results of one study by Speliotes et al. at the Massachusetts General Hospital showed that certain inherited variations in lipid metabolism precede and possibly lead to the development of liver disease. Variation of the PNPLA3 gene correlates with an increased risk of severe histologic features of NAFLD without having a strong effect on metabolic syndrome component traits. The PNPLA3 gene produces adiponutrin, a protein that seems to help regulate the production of adipocytes, lipogenesis, and lipolysis in hepatocytes and adipocytes. PNPLA3 appears to be part of a family of enzymes that affect lipid metabolism. Altered lipid metabolism, particularly within the liver, can affect fat accumulation, subsequent development of NAFLD, and possibly NASH. Genetic analyses may allow researchers to chart the causal pathways that lead to disease complications of NAFLD and other metabolic risk factors to potentially target them for therapeutic intervention.
Results from a recent Temple University study by Gerhard et al. showed that increased expression of the AEBP1 gene correlates with the severity of liver ﬁbrosis in patients with NASH. Having the AEBP1 gene appears to correlate with the onset and severity of ﬁbrosis in NASH patients, suggesting that AEBP1 may represent a speciﬁc therapeutic target to prevent development of NASH ﬁbrosis.
NAFLD is usually asymptomatic. However, some patients report feeling tired or experience discomfort in the right upper quadrant of the abdomen if they have progressed to NASH or cirrhosis. NASH can be diagnosed using bloodwork (NASH Fibrosure) or imaging (Elastography) ; however, needle biopsy is considered to be the diagnostic “gold” standard.
A serious concern with respect to diagnosis and treatment of NASH is the growing obesity rate. In 10 years, there may be more than a 50% annual increase in NASH patients needing a liver transplant.
The basic and most effective strategy for treating NASH is for patients to improve their overall health by changing their lifestyles. Steps include:
Lowering high blood pressure
Eating a low-fat diet
Lowering triglyceride and cholesterol levels
Getting more exercise
In patients with type II Diabetes Mellitus, pioglitazone (Actos), should be considered as it has been shown to reduce ﬁbrosis, steatosis, and inﬂammation. Vitamin-E supplementation may also be useful in noncirrhotic patients with biopsy conﬁrmed steatohepatitis.
Recently, use of obeticholic acid (Ocaliva), an agonist of the farnesoid X receptor that was approved by the US Food and Drug Administration to treat primary biliary cholangitis, was shown to signiﬁcantly improve regression of ﬁbrosis in NASH patients. The Randomized Global Phase 3 Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment (REGENERATE) was conducted by the National Institutes of Health and is now in phase-III testing with 931 patients. Results have shown a 28% rate of ﬁbrosis regression, and a signiﬁcant number of study patients showed normalization of liver enzyme levels.
NASH, whether driven by genetics, body composition, dietary indiscretion, use of toxic medications, or possible viral infections, still remains a mostly elusive condition in cause, prognosis, and management. More complete information on its etiology, diagnosis, and treatment ultimately will lead to a healthier population and a lesser demand for liver transplantation.
This article is PART 2 of a CME topic on transaminitis and fatty liver disease.
Take the CME test (covering Part I and Part II) FREE online CME Test on our APP - click here and enter a valid email
Become a Premium APP member? Membership info.
Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364.
Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.
Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012; 35:66-75.
Bril F, Kalavalapalli S, Clark VC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16:558-566.e2.
Chopra S, Lai M. Management of nonalcoholic fatty liver disease in adults. UpToDate Web site. Updated June 24, 2019. Accessed August 15, 2019.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.
Gerhard GS, Hanson A, Wilhelmsen D, et al. AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p. PLoS One. 2019;14:e0219764.
Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology. 2006;43:1168.
Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of D-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997;113:1069–1073.
Kirkendoll SM. NASH may overtake hepatitis C as top liver transplant cause. M Health Lab Web site. October 31, 2017. Accessed August 15, 2019.
Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–169.
Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-436.
Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:412–423.
Nonalcoholic fatty liver disease. Barnes-Jewish St. Peters Hospital Web site. Accessed August 15, 2019.
Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol (N.Y.) 2012;8:305-312.
Patal B, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2013;17:533-vii.
Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44:34–87
Rivera C. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology. 2008;15:109-114.
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362:1675-1685.
Shteyer E, Villenchik R, Mahamid M, Mator N, Safadi R. Low serum lysosomal acid lipase activity correlates with advanced liver disease. Int J Mol Sci. 2016;17:312.
Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017;23:1-12.
Younossi Z, Lavine JE, Charlton M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
Zoler ML. Obeticholic acid reversed NASH liver fibrosis in phase 3 trial. MDEdge Web site. April 12, 2019. Accessed August 15, 2019. .